June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer Cachexia Conference on Sunday, September 16 2018 in Philadelphia, organized by the Cancer Cachexia Society. Immuneering is also proud to sponsor this important event, and to be a part of community of researchers working to develop effective treatments for this significant unmet need.
About Cancer Cachexia:
According to the Cancer Cachexia Society, “Cancer cachexia is characterized as a multifactorial syndrome defined by an ongoing loss of adipose and skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Current data indicate that more than half of all cancer patients show evidence of the cachexia syndrome, leading to substantial impairment of respiratory muscle function and contributing to poor quality of life and decreased survival.”
Immuneering is fundamentally re-engineering the process by which new medicines are discovered and developed to be faster, less expensive, and more likely to succeed. The company’s proprietary drug discovery platform identifies “hits” (the molecular structures that form the basis of new medicines) in a matter of days or weeks, rather than the months or years of target identification and high-throughput screening typically required. This acceleration is made possible by applying artificial intelligence (AI) and other advanced algorithms to high-throughput data, and draws on Immuneering’s decade of experience in applying high-throughput data to pharmaceutical R&D. Immuneering’s team of experts also provides world-class bioinformatics and computational biology services.